Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MATT HOW ARE YOU JOKER LOOK LIKE WHAT I SAID ABOUT DNAP IS TRUE. HOW DOES IT FEEL TO BE TAKING IN BY A BUNCH OF PUMPERS??????
Matt you are a big joke, and will you please read this. By: tdiamonds
11 Feb 2005, 04:48 AM EST
Msg. 320869 of 320878
Jump to msg. #
Newbies - beware the PUMP & DUMP (Part 1)
This is a message I posted for months. Please feel free to check my posting history against the performance of this stock:
http://stockcharts.com/webcgi/perf.html?DNAP
ENJOY:
If you have stumbled onto this message board, I can only hope that the following post helps you to make a responsible investment decision. This is a PUMP & DUMP, at least for the short term. There are certain posters here who make up a rather formidable Boiler Room. They will try to trick you into buying this stock, even though they know it is going nowhere as a result of a convertible debenture financial agreement between DNAP and a company referred to here simply as La Jolla.
The DUMP:
For you to best understand the nature of this PUMP and DUMP, it would probably be better if you understood the DUMP, first. You will need to read the part about the convertible debenture. Please pay special attention to the table (I have posted it below) that gives approximate numbers for various share prices. I think you will find that hundreds of millions of shares will have to be DUMPed into the float for DNAP to get its funding.
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001144204%2D03%2D008459%2Etxt&FilePath...
This table was based on a current share price of $.05 when published.
% Below
Outstanding....... Price per.......With Discount........#of Shares............%
Market..................Share.............at 20%................Issuable...........Stock
25%..................$0.0375...........$0.030*............259,166,667.......33.87%
50%..................$0.0250...........$0.020*............392,500,000.......43.50%
75%..................$0.0125...........$0.010*............792,500,000.......60.58%
I particularly like this statement:
There is no upper limit on the number of shares that may be issued which will have the effect of further diluting the proportionate equity interest and voting power of holders of our common stock, including investors in this offering.
As a result, there will probably be no news strong enough (Work2Pump has stated as much) to overcome this HUGE dilution, and any run will necessarily be quashed by La Jolla’s DUMPing. Interestingly, the company calls this an investment. The way I see it, La Jolla gets shares at 20% discount to market and then DUMPs them into the float. Part of the profit goes to DNAP and the rest to La Jolla. Just exactly where is the investment? BTW, La Jolla can never hold more than 5% of DNAP shares, so how can they be investing?
The PUMP:
There are two PUMPs into this overwhelming DUMP. One is by the company itself, the other is by the boiler room on the message board.
The PUMP by the boiler room:
This is what the boiler room (Work2play seems to be the leader and Goliath a wannabe who is apparently stuck a bundle) lists as the DD page for new investors (pay special attention to the title):
http://ragingbull.lycos.com/mboard/boards.cgi?board=DNAP&read=304538
http://ragingbull.lycos.com/mboard/boards.cgi?board=DNAP&read=305094
Now ask yourself if that’s what you consider due diligence. If you only want to read half-baked BS that confirms an investment decision, there really is no need for you to read any further. Buy as much as you can afford and good luck to you. On the other hand, if your idea of due diligence means looking at the good and the bad, then you will realize this is no due diligence page at all - just a PUMP sheet to trick unsuspecting investors.
More importantly, the boiler room has been caught PUMPing into a mini-run (destined for failure) even though they knew (a) La Jolla would dump into a run; (b) there would probably never be news good enough to DUMP even the lion’s share of the hundreds of millions of shares La Jolla would have to DUMP for DNAP to get all of the money it is after. That is, they PUMPed knowing that investors would be trapped! Sounds like stock manipulation to me!
The PUMP by the company:
If you are even the least bit sophisticated about investing in stocks, you should realize that with all of the above-mentioned planned dilution the company would have to come up with some fluff PRs.
I direct your attention to the so-called DD page.
1. This one is more fluff than PUMP. The collaboration with the famous genetic epidemiologist was bought by DNAP! Basically, DNAP has agreed to fund a position in the epidemiologist’s lab. The money is going to the genetic epidemiologist, which signifies three things: (a) the genetic epidemiologist is probably bona fide; (b) DNAP is apparently not doing this research in its own lab: (c) DNAP can send shareholders’ money anywhere it wants. Interestingly, if you wanted to fund a position in this famous scientist’s lab, I am sure he would probably be more than willing to accommodate your contribution.
2. This one is pure PUMP! This so-called analyst report cost DNAP $28,000, which, once again, signifies that DNAP can send shareholders’ money anywhere it wants. To judge the efficacy of the report, you might ask yourself why the analyst failed to mention the IMPACT of the hundreds of millions of shares being DUMPed into the float. Would not your own due diligence consider such HUGE dilution to be an important factor before you parted with your own money? Why did this analyst fail to mention the impact? Was it the fact that they were paid $28,000? I will let you be the judge.
Nobody is losing any money.
The quintessential quality of a boiler room is, of course, the attempt to convince the marks that no one is losing any money, when everyone KNOWS they are. Here is one of the boiler room con artists, CosmicLifeForm, trying to convince the board of just that (303943):
I checked my number of DNAP shares and I still have them, so I haven't lost any shares. And I checked my bank account and I haven't lost any money in that either.
Anything else in my securities account is a gain/loss paper game...and you only lose money for real when you sell for less than you bought it for.
Does this liar think a four year old car is worth the same money today as it was four years ago, when it was new - just because he hasn’t sold it? Do you think he tells the insurance company he still wants to pay collision on the new car value (because that's what it's worth, given he has not sold it) I don't think so!
The complete denial of culpability:
Check out what this boiler room con artist, Arch/GCBR, said recently, when the investment started to look very shaky and one long time investor was worried about losing money (post 304728).
If you over extended yourself in a penny stock that is not our problem. It is not DNAP's problem. You knew the risks when you tried to make a millon.
Dont lay that on us---you flat out blew it. I dont want to hear about what the company said or anything else.
If you got yourself in a bind with a penny stock then you have a problem.
Oh yes, the boiler room is right there to PUMP, PUMP, PUMP over 7,000 PUMPs for this guy, but after the company lies to you, the boiler room lies to you, or suckers you into buying when they know La Jolla will DUMP into any run, and you lose your ass - you have a major assss chewing coming from the very same people who promised you da mooooooooon.
I am not a lawyer, accountant, or stock broker, so please do your own DD and invest your family's money responsibly. PLEASE consult a professional before buying or continuing to hold any risky investment.
The truth is out there,
td
- - - - -
View Replies »
Advertisements
• Trade like a pro with Qcharts
• Try Livecharts free for 14 days!
« DNAP Message list / Reply to msg. / Post new msg. « Older / Newer »
FLUFF PR DID NOT WORK THIS TIME ,PEOPLE ARE LEARNING.
GERBER BABY I HAVE SMELL NAPALM IN THE MORNING AND I LIKE IT, SO BRING IT ON. HATE THE TRUTH THERE GERBER BABY.
SCHB IS DROPPING THE BID, SO MUCH FOR THAT RUN.
People are getting smarter to DNAP way of dong business, that is put out FLUFF PR THEN SELL SHARES. JMHO BUT SCHB IS THE SELLER FOR DNAP NOW.
WHEN IS THIS GOING TO COME ABOUT? The clinical trial for OVANOME will be finished in early 2004. An application for approval to market, if required, will be submitted to the FDA by mid-2004 and approval obtained by early 2005. DNAP has a patent pending for compositions and methods relating to OVANOME. Sales of the OVANOME products to labs in 2005 will result in income of $4 million. This product launch will create a new, emerging US market of over $16 million. OVANOME is forecast to reach a peak-year sales record of $12 million in year three and hold steady for several years as the classifier test of choice in this market niche.
HOW MUCH OF THIS HAS CAME TRUE? Dear Shareholders,
I am happy to send you our second company newsletter. First, let me say that I consider DNAPrint?s scientific achievements thus far to be a great success. Rest assured, however, that our efforts are just beginning. We have written, applied and patented some of the most algorithmically complex and advanced genomics data analysis programs on the planet. In one year, these algorithms have helped us solve genetic problems (such as variable human iris color) that had perplexed geneticists for decades. I believe that your investment has helped create a formidable player in the genomics based testing market.
The Company has seen many developments since our last newsletter. We have changed the composition of our Board, announced several new scientific partners, and announced the discovery of three new forensics classifiers and their imminent product launches. We have also achieved a significant equipment upgrade that reduced our overhead and accelerated our throughput - at no cost to us. Further, we announced our foray into commercial genotyping, which we expect will help establish a revenue base upon which to grow. I will discuss some of these items one by one:
RETINOME - We have announced our intention to have either a beta trial or a partnership with a large company in place by the end of the year. This is an important part of our business strategy you should understand. We would prefer to partner our products with capable partners so we can devote ourselves to discovery and grow our revenue base more rapidly. However, if we cannot obtain satisfactory terms from a prospective partner, we will market a given test ourselves. This would provide us more profit from each test, but would increase product development costs and reduce the number of tests we could develop. We are currently in discussions with four large corporations to help us commercialize this test.
On a different note, my recent Washington D.C. presentation for RETINOME was very well received. In fact, I sensed that people are shocked that such a small company could do what we have done. Realize that RETINOME is the first complex genetics classifier to be presented in the post human genome age. Larger companies with more resources have yet to announce such a development - some have announced SNPs or haplotype associations, but we are the first to present a complex genetics classifier that performs well upon blind challenge. This bodes very well for our ability to make drug classifiers since most of these will also be complex! As we have always maintained, the key is our math.
OVANOME - Earlier this year, our University of Miami collaborators and I presented the results of our Ovarian Cancer pharmacogenomics study at the Society of Gynecological Oncology Miami and at BIOIT Boston. Our study is unique because we are focused on the variable response to firstline treatment (a pharmacokinetic problem, not a tumor genetics problem). To my knowledge, we are the only company with successful results there. We have applied for an NIH grant to fund a prospective trial at Miami, the data from which will go into an FDA application so that we could be approved to sell the kits. Until this process is complete, we will offer Taxol genotyping services (preferably through a licensee), which are not subject to FDA regulation. This brings up a second point that you should understand about our drug classifier strategy (as opposed to our forensics test strategy). For each kit we produce, there will be a service phase and a supply phase. Making an FDA approved kit (i.e., the supply phase) is more profitable, but it takes time to get kits approved by the FDA. So, until we receive FDA approval for our drug classification kits, we will perform services using our kits ourselves (i.e., the service phase). Companies like Myriad Genetics have had great success performing genetics testing services. In the case of the Taxol classifier, our licensees and affiliates will begin performing classifications for prospective Taxol patients at the University of Miami while we compile the FDA application. We will add future customer sites based on customer satisfaction at the primary sites, and we hope that word of mouth will travel fast since peoples? lives are at stake. We believe that this service/supply commercialization model will help us maximize return on investment.
OTHER TESTS - We have finished both the genotyping and the computational screening for Lipitor and Zocor, and we have finished the genotyping but not the computational screening for about 15 other drugs we have good sample sizes for. As we complete these projects, we will disclose the results within a formal, peer-reviewed setting such as a professional meeting or in the scientific literature.
SNPs - From a screen of thousands of SNPs, we have settled on a panel of 346 SNPs in about 50 xenobiotic metabolism genes for our pharmacogenomics screening. These SNPs have good characteristics (minor allele frequencies) for the sample sizes we employ - which mean they are of potentially good statistical use. Validated SNP panels like this one, of potential statistical value, are not easy to find and impossible to purchase - the chip-based sets available commercially typically apply onlyto a few cytochrome P450s, but our set covers 50 genes. We are quite proud of this panel.
ACADEMIC DEALS - We have inked new deals with the New York University and Penn State University, and added a world-renowned geneticist to our Scientific Advisory Board. These agreements supplement our existing agreement with the University of Miami. The fact that some of the nation?s leading medical universities want to work with DNAPrint speaks highly of our science.
CORPORATE - Earlier in the year, we changed the composition of our board of directors. Our new board members are providing top-notch advice and are prospecting for new deals and corporate investors. To help with this, we have consulted with professionals to greatly simplify and update our business/marketing plan. Our existing $2M funding source for the next year or so has so far been quite reliable (about $650,000 of it has so far been funded). I think it reflects favorably on our company that friends, officers and directors prefer to fund it rather than offer the opportunity to an outside venture group. We are currently evaluating and planning for our research needs after the existing funding term, and we will continue discussing this topic in the upcoming months.
OTHER ITEMS - So far, we have filed for a total of 8 patents - 5 mathematical methods/software patents and 3 classifier patents. Four of these have been converted to date to regular utility patent applications, the other four are to be converted within the year. We add data to each provisional over the course of time to make it as strong as possible before converting it. The patent process is an ongoing process, of course, as they naturally flow from our work here. The patents filed here at DNAPrint are my life's greatest scientific achievements, by far. Mostly because of the challenging level on which the work has been performed, I find them more rewarding than others I have been involved with in the past. We have written 2 scientific manuscripts and are writing a third. For products that may be partnered, the publication dates are set through the process of negotiation (i.e. we are not a University and we do not rush to publish everything we have as soon as we have it.). We have 4 grant applications pending at present and 2 more in preparation.
While we cannot control the financial markets or the financial performance of our partners, we can control the quality of work we do. We believe our share price will ultimately reflect this quality, in addition to the quality of our business decisions. Keep in mind, however, that our aim is to build a company for the long term. I know most of you are long-term investors, and it is with your interests in mind that we shape every decision made here. I think we have performed well to date and I hope you agree.
Until the next newsletter then,
Respectfully,
Tony
Public Reply / Private
GERBER BABY it get me to have someone like you get on this board and pump this stock like you do. You know what I say is the truth, you just do not want to face it. NO NEWS(FEB 7, 2004)- NO PATENTS- HIGH PAYED MANAGEMENT- LIVING OFF SHAREHOLDERS MONEY. GERBER BABY GET DNAP MANAGEMENT A CALENDAR THEY NEED ONE. JMHO
It hard to understand how anyone could say its good to have a low PPS, but leave it to pumpers they have. DNAP MANAGEMENT could slap the pumpers in the face they put a good twist on it. THIS IS A ----ONE CENT STOCK--- LIVING OFF OF SHAREHOLDERS MONEY. JMHO
Sorry about the repeats.
TRUTH HURT DOES IT NOT GUMBALL.
ARE SHAREHOLDERS GETTING PAYED????????
DR FRUDAKIS IS STILL GETTING PAYED BIG TIME. The only problem is it not from making money it from using shareholder MONEY. THAT THE FACTS MAN!!!!! If he not happy let him quit. JMHO
I know that but they still get the money so what the different.
For the last two days DNAP has not used RECAP to sell shares, but I think they switch to SCHB we wiil see this AM.
This post from RB gets to the point, how DNAP MANAGEMENT LIVES WITH SHAREHOLDERS MONEY. DNAP sounds like they just started thier business yesterday. They are going to hire a secretary, an accountant and a scientist WOW I am so impressed. I think a group of 1 st year college students could have done better in 5 years!!!! NITYA and Spyder24 keep up the good work. I too have been long 5 years haven't sold a share where's my (your) loyalty payoff in Frudakis' pocket, parking lot, yacht, and mansion LOL speculation as to the where the money went. Maybe ask his sister what's her name CARRIE nothing like keeping it in the family. Kuhnie is right at least Dick Hall knew how to make sheet up when there was nothing there how do you think this pos sheet hit .47. He was also paid in shares and wanted maximum return for his cut not to stupid really. My faith is gone and DNAP showed me why there is no point in keeping it.EY.
If DNAP has a great product after FIVE YEARS I do not think it would be a -----ONE CENT-----STOCK. NO NEWS-NO PATENTS= NO TRUST IN DNAP HIGH PAYED MANAGEMENT. JMHO
Where has it go them and shareholders a - ONE CENT STOCK-. I sure am glad I do not owe stock in some of other company that are not the leaders.
466,000 DNA TESTING COMPANIES per yahoo search. NOW WHAT MAKE DNAP SO SPECIAL!!
You keep posting about what DNAP could do in the future, WHAT ABOUT NOW? NO NEWS- NO PATENTS= ONE CENT STOCK
GERBER BABY DNA company are a dime a dozen. If being DNA company is so great why is DNAP LIVING OFF OF SHAREHOLDERS MONEY? --------ONE CENT STOCK------------
Where is the news and patents talk and no action.
Why do you keep pumping this stock with no great news and no patents? The only thing DNAP MANAGEMENT is good at is spending shareholders money. JMHO
Man where do think when RECAP IS SELLING THAT THE MONEY GOES TO? Anybody in their right mind knows DNAP HAS TO SELL SHARES TO PAY MANAGEMENT HIGH SALARIES. This company sure is not making that kind of money.
Well at the least RECAP AND DNAP were not selling shares today. Can DNAP MANAGEMENT be trust to look out for shareholders? Where is the NEWS? jmho
No it not a issue as long as that SELL-SELL SHARES.
If this was DNAP management would have a PR out now so they could SELL-SELL-SELL more shares. JMHO
How many DNA labs are there in FLORIDA, plus DNAP did not show up in this report for sure. Where is the great NEWS DNAP, JUST THE FACTS PLEASE?
All I saying is this stock should not be pumped at ALL till that give us GREAT NEWS. Where are the patents news anything but fluff PR? JMHO
May I ask why are you still pumping, when there is no news?
Where is the GREAT NEWS? Has anyone talk to a LIVE HUMAN BEING with DNAP MANAGEMENT about what going on?
The pumpers are sure woking overtime the last few days. Maybe they know something like DNAP will gap this AM, but I think they know it not going to be good. JMHO
TODAY IS THE DAY FEB. 7 2005. If DNAP and RECAP started selling this AM it will be business as usual SELL-SELL-SELL. DNAP MUST GAP UP BIG THIS AM. It been FIVE YEARS and still a ONE CENT STOCK. Maybe it will gap, but if it does not then will the pumpers please see the FACTS, DNAP is using shareholders money to pay these HIGH SALARIES. JMHO
I think most people knows what DNAP MANAGEMENT plans are, that being keep their HIGH SALARIES at any cost. If it mean SELLING BILLION AND BILLION OF SHARES so be it. JMHO
Every time RECAP get off ask the PPS goes up.
I do not think it is good news, if it was they would wait to sell. DNAP = RECAP= SELLING SHARES
Why is DNAP selling before good news??????? It look like DNAP management is needing money for their high salaries. JMHO
DNAP AND RECAP ARE SELLING AGAIN CAME BACK ON ASK AT 12:06PM TODAY. If there is good news coming why would DNAP be selling again?
FEBRUARY 07 2005 THE DAY OF RECKONING.